Piqray (alpelisib) - Novartis
Piqray: Regulatory submissions in US for HER2+ breast cancer, TNBC, 2L/3L HNSCC and ovarian cancer in 2023 or later (Novartis) - Jul 18, 2019 - Q2 2019 Results: CHMP opinion in EU for breast cancer in H2 2019 
European regulatory • sNDA
https://www.novartis.com/sites/www.novartis.com/files/q2-2019-ir-presentation.pdf
 
Jul 18, 2019
 
 
2c9a3749-b257-49e9-a72c-c1d218af655c.jpg

72537c03-c581-4ba7-b602-34966400868f.jpg